A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis.

ABSTRACT:

Objective

Prior studies of hypochondriasis demonstrated benefits for pharmacotherapy and for cognitive-behavioral therapy (CBT). This study examined whether joint treatment offers additional benefit.

Method

Patients with DSM-IV hypochondriasis (N=195) were randomly assigned to one of four treatments-placebo, CBT, fluoxetine, or joint treatment with both fluoxetine and CBT. Evaluations assessed hypochondriasis, other psychopathology, adverse events, functional status, and quality of life. The primary analysis assessed outcome at week 24 among the intent-to-treat sample, with responders defined as having a 25% or greater improvement over baseline on both the Whiteley Index and a modified version of the Yale-Brown Obsessive Compulsive Scale for hypochondriasis (H-YBOCS-M). The

SUBMITTER: Fallon BA 

PROVIDER: S-EPMC5957509 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature